Bloody Diarrhea and Shiga Toxin-Producing Escherichia coli Hemolytic Uremic Syndrome in Children: Data from the ItalKid-HUS Network.


Journal

The Journal of pediatrics
ISSN: 1097-6833
Titre abrégé: J Pediatr
Pays: United States
ID NLM: 0375410

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 10 02 2021
revised: 03 06 2021
accepted: 22 06 2021
pubmed: 2 7 2021
medline: 27 11 2021
entrez: 1 7 2021
Statut: ppublish

Résumé

To analyze the results of an enhanced laboratory-surveillance protocol for bloody diarrhea aimed at identifying children with Shiga toxin-producing Escherichia coli (STEC) infection early in the course of the disease toward the early identification and management of patients with hemolytic uremic syndrome (HUS). The study (2010-2019) involved a referral population of 2.3 million children. Stool samples of patients with bloody diarrhea were screened for Shiga toxin (Stx) genes. Positive patients were rehydrated and monitored for hemoglobinuria until diarrhea resolved or STEC-HUS was diagnosed. A total of 4767 children were screened; 214 (4.5%) were positive for either Stx1 (29.0%) or Stx2 (45.3%) or both Stx1+2 (25.7%); 34 patients (15.9%) developed STEC-HUS (0.71% of bloody diarrheas). Hemoglobinuria was present in all patients with HUS. Patients with Stx2 alone showed a greater risk of STEC-HUS (23.7% vs 12.7%) and none of the patients with Stx1 alone developed HUS. During the same period of time, 95 other patients were diagnosed STEC-HUS but were not captured by the screening program (26 had nonbloody diarrhea, 11 came from areas not covered by the screening program, and 58 had not been referred to the screening program, although they did meet the inclusion criteria). At HUS presentation, serum creatinine of patients identified by screening was significantly lower compared with that of the remaining patients (median 0.9 vs 1.51 mg/dL). Nearly 1% of children with bloody diarrhea developed STEC-HUS, and its diagnosis was anticipated by the screening program for Stx. The screening of bloody diarrhea for Stx is recommended, and monitoring patients carrying Stx2 with urine dipstick for hemoglobinuria is suggested to identify the renal complication as early as possible.

Identifiants

pubmed: 34197890
pii: S0022-3476(21)00630-2
doi: 10.1016/j.jpeds.2021.06.048
pii:
doi:

Substances chimiques

Shiga Toxins 0

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-40.e1

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Gianluigi Ardissino (G)

Center for HUS Prevention Control and Management, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milano. Electronic address: ardissino@centroseu.org.

Chiara Vignati (C)

Laboratory of Microbiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.

Carla Masia (C)

Laboratory of Microbiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.

Valentina Capone (V)

Center for HUS Prevention Control and Management, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milano.

Rosaria Colombo (R)

Laboratory of Microbiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.

Francesca Tel (F)

Department of Pediatrics, Vittore Buzzi Children's Hospital, Milano.

Laura Daprai (L)

Laboratory of Microbiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.

Sara Testa (S)

Center for HUS Prevention Control and Management, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milano.

Antonella Dodaro (A)

Laboratory of Microbiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.

Fabio Paglialonga (F)

Center for HUS Prevention Control and Management, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milano.

Mario Luini (M)

Lombardia and Emilia Romagna Experimental Zootechnic Institute (IZSLER), Lodi; Institute of Agricultural Biology and Biotechnology, National Research Council, Lodi.

Maurizio Brigotti (M)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna.

Damiano Picicco (D)

ASL 1 Imperiese: Azienda Sanitaria Locale 1 Imperiese - Ospedale di Sanremo, Sanremo.

Carlo Baldioli (C)

Pediatric Unit, Ospedale Pia Luvini, ASST-Sette Laghi-Università Insubria, Cittiglio.

Franca Pagani (F)

Department of Laboratory Medicine, Fondazione Poliambulanza Istituto Ospedaliero, Brescia.

Rossella Ceruti (R)

Department of Laboratory Medicine, Azienda Ospedaliera Carlo Poma, Mantova.

Paola Tommasi (P)

Department of Pediatrics, Vittore Buzzi Children's Hospital, Milano.

Ilaria Possenti (I)

Pediatric Unit, Ospedale Infantile C. Arrigo, Alessandria.

Donata Cresseri (D)

Nephrology and Dialysis Unit, Center for HUS Prevention Control and Management, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.

Dario Consonni (D)

Epidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.

Giovanni Montini (G)

Center for HUS Prevention Control and Management, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milano; Department of Clinical Sciences and Community Health, University of Milan, Milano.

Milena Arghittu (M)

Azienda socio sanitaria territoriale (ASST) Melegnano e della Martesana - Vizzolo Predabissi, Milano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH